347 related articles for article (PubMed ID: 38147202)
1. Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date.
Yan M; Wang H; Wei R; Li W
Arch Pharm Res; 2024 Mar; 47(3):249-271. PubMed ID: 38147202
[TBL] [Abstract][Full Text] [Related]
2. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
[TBL] [Abstract][Full Text] [Related]
3. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
Huang CH; Chen WJ; Wu CC; Chen YC; Lee YT
Pacing Clin Electrophysiol; 1999 Jun; 22(6 Pt 1):965-7. PubMed ID: 10392399
[TBL] [Abstract][Full Text] [Related]
4. Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.
Gupta S; Bagel B; Gujral S; Subramanian PG; Khattry N; Menon H; Nair R
Leuk Lymphoma; 2012 Nov; 53(11):2192-4. PubMed ID: 22452590
[TBL] [Abstract][Full Text] [Related]
5. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
Westervelt P; Brown RA; Adkins DR; Khoury H; Curtin P; Hurd D; Luger SM; Ma MK; Ley TJ; DiPersio JF
Blood; 2001 Jul; 98(2):266-71. PubMed ID: 11435292
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
Kuriyama K
Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
[No Abstract] [Full Text] [Related]
7. Arsenic trioxide.
Litzow MR
Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
9. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
11. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Barbey JT; Soignet S
Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116
[No Abstract] [Full Text] [Related]
12. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
[No Abstract] [Full Text] [Related]
13. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Galm O; Fabry U; Osieka R
Leukemia; 2000 Feb; 14(2):343-4. PubMed ID: 10673758
[No Abstract] [Full Text] [Related]
14. Does arsenic trioxide impact fertility?
Stein EM; Tallman MS
Leuk Lymphoma; 2012 Nov; 53(11):2099-100. PubMed ID: 22524541
[No Abstract] [Full Text] [Related]
15. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
Au WY; Tam S; Kwong YL
Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
[No Abstract] [Full Text] [Related]
16. Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
Kulkarni UP; Selvarajan S; Fouzia NA; Lionel S; Nair SC; Balasubramanian P; Mani T; Abraham A; George B; Mathews V
Blood Cancer J; 2023 Jun; 13(1):94. PubMed ID: 37349334
[No Abstract] [Full Text] [Related]
17. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Alimoghaddam K; Shariftabrizi A; Tavangar SM; Sanaat Z; Rostami S; Jahani M; Ghavamzadeh A
Leuk Lymphoma; 2006 Jan; 47(1):81-8. PubMed ID: 16321832
[TBL] [Abstract][Full Text] [Related]
18. Scientists explore use of arsenic in therapy.
Miller M
J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
[No Abstract] [Full Text] [Related]
19. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
20. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
Zhu H; Hu J; Chen L; Zhou W; Li X; Wang L; Zhao X; Zhang Y; Zhao H; Wang A; Chen Y; Sun H; Chen Q; Chen Y; Zhao W; Mi J; Shen Z; Wang Z; Chen Z; Chen S; Li J
Blood; 2016 Sep; 128(11):1525-8. PubMed ID: 27402972
[No Abstract] [Full Text] [Related]
[Next] [New Search]